MAINZ BIOMED NV (MYNZ) Stock Price, Quote, News and Overview
NASDAQ:MYNZ - Nasdaq - NL0015000LC2 - Common Stock - Currency: USD
MYNZ Quote, Performance and Key Statistics
MAINZ BIOMED NV
NASDAQ:MYNZ (1/31/2025, 8:00:01 PM)
After market: 6.5154 +0.43 (+6.99%)6.09
+0.75 (+14.04%)
The current stock price of MYNZ is 6.09 USD. In the past month the price increased by 40.97%. In the past year, price decreased by -82.6%.
MYNZ Latest News, Press Releases and Analysis
Which stocks are moving after the closing bell on Friday?
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements...
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population...
MYNZ Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.11 | 324.98B | ||
| AMGN | AMGEN INC | 14.85 | 153.42B | ||
| GILD | GILEAD SCIENCES INC | 21.94 | 121.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 905.25 | 118.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.81 | 73.95B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.99B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.83B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.95B | ||
| NTRA | NATERA INC | N/A | 23.36B | ||
| BIIB | BIOGEN INC | 8.81 | 20.97B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.86B |
Related stock screener links
About MYNZ
Company Profile
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The company is headquartered in Mainz, Hessen and currently employs 65 full-time employees. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Company Info
MAINZ BIOMED NV
Sirius Gutenberg Park, Robert-Koch-Strasse 50
MAINZ HESSEN DE
Employees: 65
Company Website: https://www.mainzbiomed.com/
Investor Relations: https://mainzbiomed.com/investors/
Phone: 4961315542860
MYNZ FAQ
What is the stock price of MYNZ?
The current stock price of MYNZ is 6.09 USD.
What is the symbol for MAINZ BIOMED NV stock?
The exchange symbol of MAINZ BIOMED NV is MYNZ and it is listed on the Nasdaq exchange.
On which exchange is MYNZ stock listed?
MYNZ stock is listed on the Nasdaq exchange.
Is MYNZ a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for MYNZ, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of MYNZ.
Does MYNZ stock pay dividends?
MYNZ does not pay a dividend.
What is the Price/Earnings (PE) ratio of MYNZ?
MYNZ does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.64).
MYNZ Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MYNZ. When comparing the yearly performance of all stocks, MYNZ is a bad performer in the overall market: 97.05% of all stocks are doing better.
MYNZ Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MYNZ. Both the profitability and financial health of MYNZ have multiple concerns.
MYNZ Financial Highlights
Over the last trailing twelve months MYNZ reported a non-GAAP Earnings per Share(EPS) of -1.64. The EPS increased by -3381.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -311.04% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MYNZ Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to MYNZ. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of -1367.8% and a revenue growth 13.81% for MYNZ